Miroestrol (0.1-1 mg/kg; s.c. once daily for 60 days) exhibits bone loss prevention via increase of the ratio of osteoprotegerin to receptor activator of nuclear factor kappa B ligand (osteoformation/osteoresorption) in ovariectomized mouse liver[2]. Miroestrol (0.1-1 mg/kg; i.p. once daily for 8 weeks) dose-dependently attenuates ovariectomized-induced cognitive dysfunction in mice[3]. Miroestrol (0.5-5 mg/kg; s.c. once daily for 7 days) suppresses hepatic CYP1A1 activity and CYP1A2 activity, expression of CYP1B1 mRNA and expression of CYP1A1/2 and CYP1B1 protein in β-naphthoflavone-treated mice[4].